D-Cycloserine treatment of Alzheimer disease

C. Randolph, J. W. Roberts, M. C. Tierney, D. Bravi, M Maral Mouradian, T. N. Chase

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Degeneration of cortical glutamatergic projections may contribute to the cognitive decline in Alzheimer disease (AD). To evaluate whether 1glutamate system stimulation might confer symptomatic benefit, we administered D-cycloserine, a putative partial indirect agonist at certain N-methyl-D-aspartate (NMDA) glutamate receptors, to 12 patients with probable AD. The patients (seven men, five women) had a mean age of 65 ± 8.4 years; Mini Mental State Examination scores ranged from 15 to 25. A dose escalation phase, in which cycloserine was given in daily oral doses from 25 to 500 mg (total of six dose levels, 1 week per dose), was followed by a 'best dose' crossover comparison with placebo under double-blind conditions. The crossover phase consisted of 2 weeks of cycloserine and 2 weeks of placebo, separated by a 1-week washout period. We observed no significant or consistent effect on neuropsychological outcome measures. The results suggest that short-term potentiation of NMDA-mediated glutamatergic transmission may not prove useful in the symptomatic treatment of Alzheimer dementia.

Original languageEnglish (US)
Pages (from-to)198-205
Number of pages8
JournalAlzheimer Disease and Associated Disorders
Volume8
Issue number3
DOIs
StatePublished - Jan 1 1994
Externally publishedYes

Fingerprint

Cycloserine
Alzheimer Disease
Placebos
Glutamate Receptors
N-Methylaspartate
N-Methyl-D-Aspartate Receptors
Therapeutics
Outcome Assessment (Health Care)

All Science Journal Classification (ASJC) codes

  • Clinical Psychology
  • Gerontology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Randolph, C. ; Roberts, J. W. ; Tierney, M. C. ; Bravi, D. ; Mouradian, M Maral ; Chase, T. N. / D-Cycloserine treatment of Alzheimer disease. In: Alzheimer Disease and Associated Disorders. 1994 ; Vol. 8, No. 3. pp. 198-205.
@article{084d171968614268b330c78c8bcfb3ee,
title = "D-Cycloserine treatment of Alzheimer disease",
abstract = "Degeneration of cortical glutamatergic projections may contribute to the cognitive decline in Alzheimer disease (AD). To evaluate whether 1glutamate system stimulation might confer symptomatic benefit, we administered D-cycloserine, a putative partial indirect agonist at certain N-methyl-D-aspartate (NMDA) glutamate receptors, to 12 patients with probable AD. The patients (seven men, five women) had a mean age of 65 ± 8.4 years; Mini Mental State Examination scores ranged from 15 to 25. A dose escalation phase, in which cycloserine was given in daily oral doses from 25 to 500 mg (total of six dose levels, 1 week per dose), was followed by a 'best dose' crossover comparison with placebo under double-blind conditions. The crossover phase consisted of 2 weeks of cycloserine and 2 weeks of placebo, separated by a 1-week washout period. We observed no significant or consistent effect on neuropsychological outcome measures. The results suggest that short-term potentiation of NMDA-mediated glutamatergic transmission may not prove useful in the symptomatic treatment of Alzheimer dementia.",
author = "C. Randolph and Roberts, {J. W.} and Tierney, {M. C.} and D. Bravi and Mouradian, {M Maral} and Chase, {T. N.}",
year = "1994",
month = "1",
day = "1",
doi = "10.1097/00002093-199408030-00006",
language = "English (US)",
volume = "8",
pages = "198--205",
journal = "Alzheimer Disease and Associated Disorders",
issn = "0893-0341",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

Randolph, C, Roberts, JW, Tierney, MC, Bravi, D, Mouradian, MM & Chase, TN 1994, 'D-Cycloserine treatment of Alzheimer disease', Alzheimer Disease and Associated Disorders, vol. 8, no. 3, pp. 198-205. https://doi.org/10.1097/00002093-199408030-00006

D-Cycloserine treatment of Alzheimer disease. / Randolph, C.; Roberts, J. W.; Tierney, M. C.; Bravi, D.; Mouradian, M Maral; Chase, T. N.

In: Alzheimer Disease and Associated Disorders, Vol. 8, No. 3, 01.01.1994, p. 198-205.

Research output: Contribution to journalArticle

TY - JOUR

T1 - D-Cycloserine treatment of Alzheimer disease

AU - Randolph, C.

AU - Roberts, J. W.

AU - Tierney, M. C.

AU - Bravi, D.

AU - Mouradian, M Maral

AU - Chase, T. N.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Degeneration of cortical glutamatergic projections may contribute to the cognitive decline in Alzheimer disease (AD). To evaluate whether 1glutamate system stimulation might confer symptomatic benefit, we administered D-cycloserine, a putative partial indirect agonist at certain N-methyl-D-aspartate (NMDA) glutamate receptors, to 12 patients with probable AD. The patients (seven men, five women) had a mean age of 65 ± 8.4 years; Mini Mental State Examination scores ranged from 15 to 25. A dose escalation phase, in which cycloserine was given in daily oral doses from 25 to 500 mg (total of six dose levels, 1 week per dose), was followed by a 'best dose' crossover comparison with placebo under double-blind conditions. The crossover phase consisted of 2 weeks of cycloserine and 2 weeks of placebo, separated by a 1-week washout period. We observed no significant or consistent effect on neuropsychological outcome measures. The results suggest that short-term potentiation of NMDA-mediated glutamatergic transmission may not prove useful in the symptomatic treatment of Alzheimer dementia.

AB - Degeneration of cortical glutamatergic projections may contribute to the cognitive decline in Alzheimer disease (AD). To evaluate whether 1glutamate system stimulation might confer symptomatic benefit, we administered D-cycloserine, a putative partial indirect agonist at certain N-methyl-D-aspartate (NMDA) glutamate receptors, to 12 patients with probable AD. The patients (seven men, five women) had a mean age of 65 ± 8.4 years; Mini Mental State Examination scores ranged from 15 to 25. A dose escalation phase, in which cycloserine was given in daily oral doses from 25 to 500 mg (total of six dose levels, 1 week per dose), was followed by a 'best dose' crossover comparison with placebo under double-blind conditions. The crossover phase consisted of 2 weeks of cycloserine and 2 weeks of placebo, separated by a 1-week washout period. We observed no significant or consistent effect on neuropsychological outcome measures. The results suggest that short-term potentiation of NMDA-mediated glutamatergic transmission may not prove useful in the symptomatic treatment of Alzheimer dementia.

UR - http://www.scopus.com/inward/record.url?scp=0028048327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028048327&partnerID=8YFLogxK

U2 - 10.1097/00002093-199408030-00006

DO - 10.1097/00002093-199408030-00006

M3 - Article

C2 - 7986489

AN - SCOPUS:0028048327

VL - 8

SP - 198

EP - 205

JO - Alzheimer Disease and Associated Disorders

JF - Alzheimer Disease and Associated Disorders

SN - 0893-0341

IS - 3

ER -